First successful transapical aortic valve implantation with the Corevalve Revalving system: a case report.
On June 26, 2007, the Clinic for Cardiovascular Surgery at the German Heart Center Technical University in Munich successfully implanted a bioprosthetic valve via the apex of the heart within the framework of the CoreValve TAVR ReValving (Corevalve Inc., Irvine, CA, USA) clinical trial. The self-expanding aortic valve prosthesis is primarily designed for retrograde delivery across the aortic valve. The described transapical approach, however, now allows for treatment in those patients who have, for instance, no adequate "access" in the groin vessels due to peripheral vascular disease. Therefore, its feasibility must be considered as a major step in treating high-risk patients.
Lange
Rüdiger
R
Clinic for Cardiovascular Surgery, German Heart Center Technical University, Munich, Germany.
Schreiber
Christian
C
Götz
Wolfgang
W
Hettich
Ina
I
Will
Albrecht
A
Libera
Paul
P
Laborde
Jean-Claude
JC
Bauernschmitt
Robert
R
D000369:Aged, 80 and over; D001021:Aortic Valve / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000000981:diagnostic imaging / Q000601:surgery*; D004452:Echocardiography; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D019918:Heart Valve Prosthesis Implantation / Q000295:instrumentation*; D006801:Humans